NIH, National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) NIH - National Institutes of Health National Cancer Institute DCTD - Division of Cancer Treatment and Diagnosis

A sensitive method to quantify human cell-free circulating DNA in blood: Relevance to myocardial infarction screening.

Author(s): Jing RR, Wang HM, Cui M, Fang MK, Qiu XJ, Wu XH, Qi J, Wang YG, Zhang LR, Zhu JH, Ju SQ

Publication: Clin Biochem, 2011, Vol. 44, Page 1074-9

PubMed ID: 21723272 PubMed Review Paper? No

Purpose of Paper

The purpose of this paper was to evaluate a new method of quantifying cell free circulating DNA (cf-DNA) to aid in the diagnosis of myocardial infarction (MI).

Conclusion of Paper

Serum had more cf-DNA than EDTA plasma. Males had significantly lower levels of cf-DNA in serum than females. The levels of cf-DNA were much higher in the plasma of patients with MI than in normal controls. There was no correlation of cf-DNA levels with creatine kinase-MB (CK-MB), troponin I (cTnI), or myoglobin (MYO).

Studies

  1. Study Purpose

    The purpose of this study was to determine the effects of blood component, gender, and diagnosis of MI on cf-DNA levels in blood. Blood was separated after collection and then frozen at -80 degrees C until all specimens were obtained. Serum was collected in serum separator tubes (SST).

    Summary of Findings:

    Serum had more cf-DNA than EDTA plasma. There was insignificantly lower cf-DNA in EDTA plasma from males than females (p>0.05), but males had significantly lower levels of cf-DNA in serum than females (mean 154.6 versus 255.8 ng/mL, P<0.05). The levels of cf-DNA were much higher in the plasma of patients with MI than in normal controls (median of 4439.4 and 117.6 ng/mL, respectively). There was no correlation of cf-DNA levels with CK-MB, cTnI, or MYO. In serially collected specimens, cf-DNA peaked before cTnI. The assay was able to accurately quantify cf-DNA at concentrations of 20-400 ng/mL with a coefficient of variance of 13.04, 7.54, and 7.53 for 20 ng/mL, 100 ng/mL and 200 ng/mL, respectively.

    Biospecimens
    Preservative Types
    • Frozen
    Diagnoses:
    • Normal
    • Cardiovascular Disease
    Platform:
    AnalyteTechnology Platform
    DNA Branch DNA assay
    Protein Immunoassay
    Pre-analytical Factors:
    ClassificationPre-analytical FactorValue(s)
    Biospecimen Aliquots and Components Blood and blood products Plasma
    Serum
    Preaquisition Diagnosis/ patient condition Myocardial infarct
    Normal
    Preaquisition Patient gender Female
    Male
    Immunoassay Specific Targeted peptide/protein Troponin 1
    Creatine kinase-MB
    Myoglobin
    Biospecimen Acquisition Time of biospecimen collection At admission
    Before angioplasty
    After angioplasty

You Recently Viewed  

News and Announcements

  • Most Downloaded SOPs in 2024

  • New Articles on the GTEx Project are Now FREELY Available!

  • Just Published!

  • More...